Cargando…
Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study
PURPOSE: The number of patients who make it to receive third-line chemotherapy is increasing owing to the improvements in adverse-event management of chemotherapy for small-cell lung cancer (SCLC). Sequencing of optimal treatment for SCLC is still a challenge for oncologists. In this paper, we aim t...
Autores principales: | Aktas, Gokmen, Kus, Tulay, Kalender, Mehmet Emin, Sevinc, Alper, Camci, Celaletdin, Kul, Seval |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824370/ https://www.ncbi.nlm.nih.gov/pubmed/27099522 http://dx.doi.org/10.2147/OTT.S101390 |
Ejemplares similares
-
Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?
por: Kus, Tulay, et al.
Publicado: (2015) -
Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib
por: Kus, Tulay, et al.
Publicado: (2015) -
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel
por: Kus, Tulay, et al.
Publicado: (2016) -
Polymorphisms in the MTHFR gene are associated with recurrence risk in lymph node-positive breast cancer patients
por: Suner, Ali, et al.
Publicado: (2016) -
Collision tumor consisting of primary follicular lymphoma and adenocarcinoma in the cecum: A case report and literature review
por: KUS, TULAY, et al.
Publicado: (2016)